Early Career Working Group Update

The NMD4C is honoured to have 92 early career clinicians and scientists as members, comprising 25 percent of total NMD4C membership. 

 

Over the past several months, a number of these members have contributed to the network through presenting as a part of the NMD4C’s CPD-accredited webinar series, sharing their experience in the neuromuscular field in blog posts, and providing a unique perspective on the network’s activities. To further support our active early-career members, the NDM4C has created a list of profiles for these members, where you can learn more about their research interests, publications, and where you can find them online. Through sharing these profiles, the NMD4C hopes to foster new collaborations between clinicians and researchers, and help to connect early-career members of the neuromuscular community with senior investigators. If you are an early career clinician or researcher, you can find out more about how you can get involved here.

 

The NMD4C has also launched an early-career Slack channel, a members-only workspace created to connect early-career clinicians and researchers in the neuromuscular community.

This resource will promote networking for early-career members who share similar neuromuscular interests, act as a platform to exchange ideas and form future collaborations, and provide insight into the diverse work of other NMD4C members. The NMD4C will post updates in this channel covering early-career initiatives, events, and other opportunities within the neuromuscular community. If you are interested in joining, please email NMD4C communications coordinator James Davis (). 

 

The NMD4C is also seeking early career member representation on all of our work packages; if you would like to get involved, please express your interest to communications coordinator James Davis.

 

In other early career news, the ENMC early-career mentoring program deadline for application is fast approaching; apply by July 1st, 2021 to express interest in application and to seek mentoring in order to become an independent researcher and/or potential future leader in the NMD field. This program is for individuals at the stage in their careers where they are developing their own research plans and are establishing their research teams and collaborative networks worldwide.

EC Update

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 26-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.